William Looney
Executive Editor, In Vivo
USA
+41 year(s) experience
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.
In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース
Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.
In Vivo: 医療用医薬品・医療機器...
18 Jan 2021
In Vivo: 医療用医薬品・医療機器...
12 Jan 2021
In Vivo: 医療用医薬品・医療機器...
16 Jul 2020
Generics Bulletin: ジ...
16 Jun 2020
In Vivo: 医療用医薬品・医療機器...
14 Nov 2019
In Vivo: 医療用医薬品・医療機器...
21 Oct 2019
In Vivo: 医療用医薬品・医療機器...
21 Aug 2019
In Vivo: 医療用医薬品・医療機器...
28 May 2019
In Vivo: 医療用医薬品・医療機器...
23 Apr 2019
In Vivo: 医療用医薬品・医療機器...
10 Apr 2019
In Vivo: 医療用医薬品・医療機器...
03 Apr 2019
In Vivo: 医療用医薬品・医療機器...
05 Mar 2019